{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:52Z","timestamp":1793176792169,"version":"4.5.0"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The novel recombinant anthrax toxin, PrAgU2\/FP59, composed of the urokinase-activated protective antigen and a fusion protein of Pseudomonas exotoxin and lethal factor was tested for anti\u2013lung cancer efficacy in an in vivo human tumor model. Male athymic nude mice (age 4\u20136 weeks) were inoculated s.c. with 10 million H1299 non\u2013small cell lung cancer (NSCLC) cells in the left flank. When tumor volumes reached 200 mm3 (6\u20138 days), i.p. injection of 100 \u03bcL saline or different ratios and doses of PrAgU2\/FP59 in 100 \u03bcL saline were given every 3 days for four doses and an additional dose at day 29. Animals were monitored twice daily and tumor measurements were made by calipers. The maximum tolerated doses of PrAgU2\/FP59 differed dependent on the ratios of PrAgU2 to FP59 over the range of 3:1 to 25:1, respectively. At tolerated doses, tumor regressions were seen in all animals. Complete histologic remission lasting 60 days occurred in 30% of animals. PrAgU2\/FP59 showed dramatic anti-NSCLC efficacy and warrants further clinical development for therapy of patients with advanced NSCLC. [Cancer Res 2007;67(7):3329\u201336]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4642","type":"journal-article","created":{"date-parts":[[2007,4,4]],"date-time":"2007-04-04T20:32:35Z","timestamp":1175718755000},"page":"3329-3336","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Systematic Urokinase-Activated Anthrax Toxin Therapy Produces Regressions of Subcutaneous Human Non\u2013Small Cell Lung Tumor in Athymic Nude Mice"],"prefix":"10.1158","volume":"67","author":[{"given":"Yunpeng","family":"Su","sequence":"first","affiliation":[{"name":"1Cancer Research Institute, Scott & White Memorial Hospital, Temple, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Ortiz","sequence":"additional","affiliation":[{"name":"1Cancer Research Institute, Scott & White Memorial Hospital, Temple, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Liu","sequence":"additional","affiliation":[{"name":"2Bacterial Toxins and Therapeutics Section, National Institute of Allergy and Infectious Diseases;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Bugge","sequence":"additional","affiliation":[{"name":"3Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravibhushan","family":"Singh","sequence":"additional","affiliation":[{"name":"1Cancer Research Institute, Scott & White Memorial Hospital, Temple, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Leppla","sequence":"additional","affiliation":[{"name":"2Bacterial Toxins and Therapeutics Section, National Institute of Allergy and Infectious Diseases;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur E.","family":"Frankel","sequence":"additional","affiliation":[{"name":"1Cancer Research Institute, Scott & White Memorial Hospital, Temple, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,4,4]]},"reference":[{"key":"2022061623194954100_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Tiwari RC, Murray T, et al. Cancer statistics 2004. CA Clin J\u20082004; 54: 8\u201329.","DOI":"10.3322\/canjclin.54.1.8"},{"key":"2022061623194954100_B2","doi-asserted-by":"crossref","unstructured":"Gridelli C. Targeted therapies and non-small-cell lung cancer: work in progress? Curr Opin Oncol\u20082006; 18: 132\u20134.","DOI":"10.1097\/01.cco.0000208785.14818.4b"},{"key":"2022061623194954100_B3","unstructured":"Fan D, Yano S, Shinohara H, et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther\u20082002; 1: 595\u2013600."},{"key":"2022061623194954100_B4","unstructured":"Skrepnik N, Araya JC, Qian Z, et al. Effects of anti-erbB-2 (HER-2\/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Clin Cancer Res\u20081996; 2: 1851\u20137."},{"key":"2022061623194954100_B5","doi-asserted-by":"crossref","unstructured":"Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost\u20082005; 93: 676\u201381.","DOI":"10.1160\/TH05-01-0054"},{"key":"2022061623194954100_B6","doi-asserted-by":"crossref","unstructured":"Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci\u20082000; 57: 25\u201340.","DOI":"10.1007\/s000180050497"},{"key":"2022061623194954100_B7","doi-asserted-by":"crossref","unstructured":"Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des\u20082004; 10: 2359\u201376.","DOI":"10.2174\/1381612043383962"},{"key":"2022061623194954100_B8","unstructured":"Alonso DF, Tejera AM, Farias EF, Bal de Kier Joffe E, Gomez DE. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res\u20081998; 18: 4499\u2013504."},{"key":"2022061623194954100_B9","doi-asserted-by":"crossref","unstructured":"Setyono-Han B, Sturzebecher J, Schmalix WA, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost\u20082005; 93: 779\u201386.","DOI":"10.1160\/TH04-11-0712"},{"key":"2022061623194954100_B10","doi-asserted-by":"crossref","unstructured":"Zeslawska E, Jacob U, Schweinitz A, Coombs G, Bode W, Madison E. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. J Mol Biol\u20082003; 328: 109\u201318.","DOI":"10.1016\/S0022-2836(03)00267-5"},{"key":"2022061623194954100_B11","doi-asserted-by":"crossref","unstructured":"Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel\u20082004; 17: 157\u201364.","DOI":"10.1093\/protein\/gzh023"},{"key":"2022061623194954100_B12","doi-asserted-by":"crossref","unstructured":"Cavallaro U, del Vecchio A, Lappi DA, Soria MR. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem\u20081993; 268: 23186\u201390.","DOI":"10.1016\/S0021-9258(19)49445-3"},{"key":"2022061623194954100_B13","doi-asserted-by":"crossref","unstructured":"Wei W, Lu Q, Chaudry GJ, Leppla SH, Cohen SN. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell\u20082006; 124: 1141\u201354.","DOI":"10.1016\/j.cell.2005.12.045"},{"key":"2022061623194954100_B14","unstructured":"Carson-Walter, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res\u20082001; 61: 6649\u201355."},{"key":"2022061623194954100_B15","doi-asserted-by":"crossref","unstructured":"Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Nat Acad Sci U S A\u20082003; 100: 5170\u20134.","DOI":"10.1073\/pnas.0431098100"},{"key":"2022061623194954100_B16","doi-asserted-by":"crossref","unstructured":"Melnyk RA, Collier RJ. A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation. Proc Natl Acad Sci U S A\u20082006; 103: 9802\u20137.","DOI":"10.1073\/pnas.0604000103"},{"key":"2022061623194954100_B17","doi-asserted-by":"crossref","unstructured":"Trujillo C, Ratts R, Tamayo A, Harrison R, Murphy JR. Trojan horse or proton force: finding the right partner(s) for toxin translocation. Neurotox Res\u20082006; 9: 63\u201371.","DOI":"10.1007\/BF03033924"},{"key":"2022061623194954100_B18","doi-asserted-by":"crossref","unstructured":"Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science\u20081998; 280: 734\u20137.","DOI":"10.1126\/science.280.5364.734"},{"key":"2022061623194954100_B19","doi-asserted-by":"crossref","unstructured":"Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem\u20082001; 276: 17976\u201384.","DOI":"10.1074\/jbc.M011085200"},{"key":"2022061623194954100_B20","doi-asserted-by":"crossref","unstructured":"Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol Cancer Ther\u20082006; 5: 2556\u201362.","DOI":"10.1158\/1535-7163.MCT-06-0315"},{"key":"2022061623194954100_B21","doi-asserted-by":"crossref","unstructured":"Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A\u20082003; 100: 657\u201362.","DOI":"10.1073\/pnas.0236849100"},{"key":"2022061623194954100_B22","doi-asserted-by":"crossref","unstructured":"Rono B, Romer J, Liu S, Bugge TH, Leppla SH, Kristjansen PE. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol Cancer Ther\u20082006; 5: 89\u201396.","DOI":"10.1158\/1535-7163.MCT-05-0163"},{"key":"2022061623194954100_B23","doi-asserted-by":"crossref","unstructured":"Arora N, Klimpel KR, Singh Y, Leppla SH. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem\u20081992; 267: 15542\u20138.","DOI":"10.1016\/S0021-9258(19)49569-0"},{"key":"2022061623194954100_B24","doi-asserted-by":"crossref","unstructured":"Liu S, Leung HJ, Leppla SH. Characterization of the interaction between anthrax toxin and its cellular receptors. Cellular Microbiology. In press 2006.","DOI":"10.1111\/j.1462-5822.2006.00845.x"},{"key":"2022061623194954100_B25","doi-asserted-by":"crossref","unstructured":"March TH, Marron-Terada PG, Belinsky SA. Refinement of an orthotopic lung cancer model in the nude rat. Vet Pathol\u20082001; 38: 483\u201390.","DOI":"10.1354\/vp.38-5-483"},{"key":"2022061623194954100_B26","doi-asserted-by":"crossref","unstructured":"Williams TA, Verhovez A, Milan A, Veglio F, Mulatero P. Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology\u20082006; 147: 2496\u2013505.","DOI":"10.1210\/en.2005-1318"},{"key":"2022061623194954100_B27","doi-asserted-by":"crossref","unstructured":"Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma\u20082001; 1: 298\u2013302.","DOI":"10.3816\/CLM.2001.n.005"},{"key":"2022061623194954100_B28","doi-asserted-by":"crossref","unstructured":"Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol\u20082000; 18: 2282\u201392.","DOI":"10.1200\/JCO.2000.18.11.2282"},{"key":"2022061623194954100_B29","unstructured":"Siegall CB, Liggitt D, Chace D, et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res\u20081997; 3: 339\u201345."},{"key":"2022061623194954100_B30","doi-asserted-by":"crossref","unstructured":"Pearson D, Altus MS, Horiuchi A, Nagamine Y. Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells. Biochem Biophys Res Commun\u20081987; 143: 329\u201336.","DOI":"10.1016\/0006-291X(87)90669-3"},{"key":"2022061623194954100_B31","doi-asserted-by":"crossref","unstructured":"Yoshida E, Tsuchiya K, Sugiki M, Sumi H, Mihara H, Maruyama M. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation\u20081996; 20: 319\u201326.","DOI":"10.1007\/BF01488206"},{"key":"2022061623194954100_B32","doi-asserted-by":"crossref","unstructured":"Sasaki CY, Lin H, Passaniti A. Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells. J Cell Physiol\u20081999; 181: 1\u201313.","DOI":"10.1002\/(SICI)1097-4652(199910)181:1<1::AID-JCP1>3.0.CO;2-B"},{"key":"2022061623194954100_B33","doi-asserted-by":"crossref","unstructured":"Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res\u20082006; 12: 7117\u201325.","DOI":"10.1158\/1078-0432.CCR-06-0760"},{"key":"2022061623194954100_B34","doi-asserted-by":"crossref","unstructured":"Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and\/or chemotherapy in lung cancer. Clin Cancer Res\u20082005; 11: 795\u2013805.","DOI":"10.1158\/1078-0432.795.11.2"},{"key":"2022061623194954100_B35","doi-asserted-by":"crossref","unstructured":"Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs\u20082004; 15: 503\u201312.","DOI":"10.1097\/01.cad.0000127664.66472.60"},{"key":"2022061623194954100_B36","doi-asserted-by":"crossref","unstructured":"Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res\u20082004; 10: 13\u20135.","DOI":"10.1158\/1078-0432.CCR-1216-3"},{"key":"2022061623194954100_B37","doi-asserted-by":"crossref","unstructured":"Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer\u20082006; 6: 225.","DOI":"10.1186\/1471-2407-6-225"},{"key":"2022061623194954100_B38","doi-asserted-by":"crossref","unstructured":"Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer\u20082006; 106: 1569\u201380.","DOI":"10.1002\/cncr.21776"},{"key":"2022061623194954100_B39","doi-asserted-by":"crossref","unstructured":"Kim CN, Bhalla K, Kreitman RJ, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res\u20081999; 23: 527\u201338.","DOI":"10.1016\/S0145-2126(99)00039-9"},{"key":"2022061623194954100_B40","doi-asserted-by":"crossref","unstructured":"Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE, et al. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res\u20082004; 28: 1221\u20136.","DOI":"10.1016\/j.leukres.2004.03.015"},{"key":"2022061623194954100_B41","doi-asserted-by":"crossref","unstructured":"Frankel AE, Hall PD, McLain C, et al. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem\u20081998; 9: 490\u20136.","DOI":"10.1021\/bc980015a"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/7\/3329\/2581596\/3329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/7\/3329\/2581596\/3329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T05:38:37Z","timestamp":1683783517000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/7\/3329\/534833\/Systematic-Urokinase-Activated-Anthrax-Toxin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2007,4,4]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4642","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496815.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496815","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22371468","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371468.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,1]]}}}